Repeat Entrepreneurship And Talent Retention Key To Success Of SV Health Investors

Interview With Houman Ashrafian, Managing Partner At SV Health Investors

In this latest installment of the VC Playbook series, In Vivo sits down with SV Health Investors’s Houman Ashrafian. The managing partner outlines the group’s investment philosophy, today’s skill set for VC success, and expectations for the future of Britain’s biotech industry post-Brexit and post-pandemic.

Tree Growing On Coins
GROWING THE TALENT POOL IS KEY TO COMPANY CREATION • Source: Alamy

Houman Ashrafian, managing partner at SV Health Investors, sat down with In Vivo to discuss insights for investment strategies and the future of biotech in the UK. Ashrafian is based in London and heads up the SV biotech team alongside managing partner Kate Bingham, who led the UK's vaccine effort last year as chair of the UK Vaccines Task Force.

“SV is deeply embedded in the innovation economy,” said Ashrafian of the venture firm, which has approximately $2.7 bn in...

More from Business Strategy

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.